Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer

被引：19

作者：

Calcagno, Fabien ^{[1
]}

Nguyen, Thierry ^{[1
]}

Dobi, Erion ^{[1
]}

Villanueva, Cristian ^{[1
]}

Curtit, Elsa ^{[1
]}

Kim, Stefano ^{[1
]}

Montcuquet, Philippe ^{[1
]}

Kleinclauss, Francois ^{[2
,3
,4
]}

Pivot, Xavier ^{[1
,2
,3
]}

Thiery-Vuillemin, Antoine ^{[1
,2
,3
]}

机构：

[1] CHU Besancon, Oncol, Besancon, France

[2] INSERM, UMR1098, Besancon, France

[3] Univ Franche Comte, UMR1098, SFR IBCT, Besancon, France

[4] CHU Besancon, Urol, Besancon, France

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2013年 / 7卷

关键词：

cabazitaxel; prostate cancer; castrate resistant; chemotherapy; taxane;

D O I：

10.4137/CMO.S7256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men with castration-resistant prostate cancer (CRPC). Cabazitaxel (XRP6258, TXD258, and RPR116258A), a tubulin-binding - taxane drug as potent as docetaxel in cell lines, was the first treatment able to prolong survival for metastatic CRPC in the post-docetaxel setting. This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed.

引用

页码：1 / 12

页数：12

共 61 条

[1] Update on tubulin-binding agents [J].

Attard, G ;

Greystoke, A ;

Kaye, S ;

De Bono, J .

PATHOLOGIE BIOLOGIE, 2006, 54 (02) :72-84

[2] A population pharmacokinetic model for docetaxel (Taxotere(R)): Model building and validation [J].

Bruno, R ;

Vivier, N ;

Vergniol, JC ;

DePhillips, SL ;

Montay, G ;

Sheiner, LB .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02) :153-172

[3] Targeting the androgen receptor pathway in prostate cancer [J].

Chen, Yu ;

Sawyers, Charles L. ;

Scher, Howard I. .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) :440-448

[4] Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets [J].

Chi, Kim N. ;

Bjartell, Anders ;

Dearnaley, David ;

Saad, Fred ;

Schroeder, Fritz H. ;

Sternberg, Cora ;

Tombal, Bertrand ;

Visakorpi, Tapio .

EUROPEAN UROLOGY, 2009, 56 (04) :594-605

[5] Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats [J].

Cisternino, S ;

Bourasset, F ;

Archimbaud, Y ;

Sémiond, D ;

Sanderink, G ;

Scherrmann, JM .

BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (07) :1367-1375

[6] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].

CRAWFORD, ED ;

EISENBERGER, MA ;

MCLEOD, DG ;

SPAULDING, JT ;

BENSON, R ;

DORR, FA ;

BLUMENSTEIN, BA ;

DAVIS, MA ;

GOODMAN, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424

[7] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[9]

De Bono JS, 2012, AM SOC CLIN ONC ASCO

[10] Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding [J].

de Bruijn, Peter ;

de Graan, Anne-Joy M. ;

Nieuweboer, Annemieke ;

Mathijssen, Ron H. J. ;

Lam, Mei-Ho ;

de Wit, Ronald ;

Wiemer, Erik A. C. ;

Loos, Walter J. .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 59 :117-122

← 1 2 3 4 5 6 7 →